Larimar Therapeutics, Inc. (LRMR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US5171251003
Larimar Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -172.50 m USD |
| EBIT | -165.67 m USD |
| Net income | -165.67 m USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
More stocks
- Anhui Chaoyue Environmental Protection Technology Co. Ltd. (301049.SZ)
- AerSale Corp (ASLE)
- Nak Sealing Technologies Corp (9942.TW)
- Tomocube Inc (475960.KQ)
- Kung Long Batteries Industrial Co Ltd (1537.TW)
- ShenZhen GAD Environmental Technology Co. Ltd. (300854.SZ)
- Azkoyen (AZK.MC)
- Fujian Yuanxiang New Materials Co. Ltd. A (301300.SZ)
- Putnam Municipal Opportunities Trust (PMO)
- Guiyang Xintian Pharmaceutical Co Ltd (002873.SZ)
- Sk Securities (001510.KS)
- Jiangsu Smartwin Electronics Technology Co.Ltd. (301106.SZ)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.